PMID- 35367521
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20220914
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 190
DP  - 2022 Aug
TI  - Extracellular vesicles derived from human umbilical cord mesenchymal stem cells 
      relieves diabetic retinopathy through a microRNA-30c-5p-dependent mechanism.
PG  - 109861
LID - S0168-8227(22)00673-8 [pii]
LID - 10.1016/j.diabres.2022.109861 [doi]
AB  - AIMS: Extracellular vesicle (EV)-transferred microRNAs (miRNAs) are proved to be 
      potentially therapeutic candidates. Here, we attempted to unveil the role of 
      delivery of miR-30c-5p by human umbilical cord mesenchymal stem cells 
      (hUCMSCs)-derived EVs in diabetic retinopathy (DR). METHODS: miR-30c-5p and PLCG1 
      expression in streptozotocin-induced diabetes mellitus (DM) rats and high glucose 
      (HG)-treated human retinal endothelial cells (HRECs) was quantified, followed by 
      analysis on their interaction. EVs were isolated from hUCMSCs and co-cultured 
      with HRECs. Through gain- and loss-of-function assays, the role of 
      hUCMSCs-derived EV containing miR-30c-5p in DR involving PLCG1 and NF-kappaB pathway 
      was analyzed in vitro and in vivo. RESULTS: Elevated PLCG1 was found in DM rats 
      and HG-treated HRECs where miR-30c-5p was reduced while increased in 
      hUCMSC-derived EVs. PLCG1 was pinpointed as a target gene of miR-30c-5p, which 
      consequently disrupted the PKC/NF-kappaB pathway. hUCMSC-derived EVs decreased 
      inflammation reaction by transferring miR-30c-5p in DM rats and HG-treated HRECs. 
      Furthermore, similar changing tendency was observed in HG-treated HRECs induced 
      by overexpressed miR-30c-5p through downregulation of PLCG1 in vivo. CONCLUSION: 
      Overall, our findings underlined delivery of miR-30c-5p by hUCMSC-derived EVs as 
      a novel suppressor in the inflammatory response following DR.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - He, Yue
AU  - He Y
AD  - Department of Ophthalmology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou 646000, PR China. Electronic address: hylyfy@163.com.
FAU - Zhang, Zhiru
AU  - Zhang Z
AD  - Department of Ophthalmology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou 646000, PR China.
FAU - Yao, Tianyu
AU  - Yao T
AD  - Department of Ophthalmology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou 646000, PR China.
FAU - Huang, Li
AU  - Huang L
AD  - Department of Ophthalmology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou 646000, PR China.
FAU - Gan, Jinhua
AU  - Gan J
AD  - Department of Ophthalmology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou 646000, PR China.
FAU - Lv, Hongbin
AU  - Lv H
AD  - Department of Ophthalmology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou 646000, PR China.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Rheumatology and Immunology, The Affiliated Hospital of Southwest 
      Medical University, Luzhou 646000, PR China. Electronic address: cjlion@qq.com.
LA  - eng
PT  - Journal Article
DEP - 20220401
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (MicroRNAs)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Animals
MH  - *Diabetes Mellitus/metabolism
MH  - *Diabetic Retinopathy/genetics/metabolism/therapy
MH  - Endothelial Cells/metabolism
MH  - *Extracellular Vesicles/metabolism
MH  - Humans
MH  - *Mesenchymal Stem Cells/metabolism
MH  - *MicroRNAs/genetics/metabolism
MH  - NF-kappa B/metabolism
MH  - Rats
MH  - Umbilical Cord/metabolism
OTO - NOTNLM
OT  - Diabetic retinopathy
OT  - Extracellular vesicles
OT  - Human umbilical cord mesenchymal stem cells
OT  - PKC/NF-kappaB pathway
OT  - PLCG1
OT  - microRNA-30c-5p
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/04/04 06:00
MHDA- 2022/09/09 06:00
CRDT- 2022/04/03 20:25
PHST- 2021/11/18 00:00 [received]
PHST- 2022/03/25 00:00 [revised]
PHST- 2022/03/29 00:00 [accepted]
PHST- 2022/04/04 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
PHST- 2022/04/03 20:25 [entrez]
AID - S0168-8227(22)00673-8 [pii]
AID - 10.1016/j.diabres.2022.109861 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2022 Aug;190:109861. doi: 10.1016/j.diabres.2022.109861. 
      Epub 2022 Apr 1.